Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Stijn Hentzen"'
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Vol 6, Iss 3, Pp 150-157 (2023)
HER2-targeted therapy with the HER2 monoclonal antibody trastuzumab has achieved impressive outcomes in the first-line settings of patients with advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma overexpressing HER2. However, conside
Externí odkaz:
https://doaj.org/article/7861da04f0254761843bc97408ee4846
Autor:
Stijn Hentzen, Kathan Mehta, Raed Moh’d Taiseer Al-Rajabi, Anwaar Saeed, Joaquina Celebre Baranda, Stephen K. Williamson, Weijing Sun, Anup Kasi
Publikováno v:
Exploration of Targeted Anti-tumor Therapy, Vol 4, Iss 3, Pp 396-405 (2023)
Aim: 177Lu-Dotatate (Lu-177), a form of peptide receptor radionuclide therapy (PRRT), was approved by Food and Drug Administration (FDA) for the treatment of somatostatin-receptor-positive neuroendocrine tumors (NETs) in 2018. Clinical trials prior t
Externí odkaz:
https://doaj.org/article/2635daac99304ae195059b489986adb0
Autor:
Aviva Atri-Schuller, Hassan Abushukair, Ludimila Cavalcante, Stijn Hentzen, Azhar Saeed, Anwaar Saeed
Publikováno v:
Current Issues in Molecular Biology, Vol 44, Iss 11, Pp 5756-5767 (2022)
Although most people are infected with Epstein-Barr Virus (EBV) during their lifetime, only a minority of them develop an EBV-associated malignancy. EBV acts in both direct and indirect ways to transform infected cells into tumor cells. There are mul
Externí odkaz:
https://doaj.org/article/fdd5b5e22700446eac2525e380cd91d9
Publikováno v:
Health Care Transitions, Vol 1, Iss , Pp 100021- (2023)
Background: As cancer prevalence increases and treatment improves, the population of childhood cancer survivors (CCS) will see remarkable growth. This population requires guideline-based survivorship care into adulthood; however, numerous gaps in car
Externí odkaz:
https://doaj.org/article/3d56bc8f557d451c91fcd566d75b2b78
Publikováno v:
Brown Journal of Hospital Medicine, Vol 1, Iss 3 (2022)
**Background:** Our institution used an automated provider alert for venous thromboembolism (VTE) prophylaxis. This alert had an option to “snooze,” generating a user-specific delay before repeat firing. Providers snoozed 67% of VTE alerts. Our a
Externí odkaz:
https://doaj.org/article/b377cd2fed204598ba477325f873cb9f
Publikováno v:
Frontiers in Bioscience-Landmark, Vol 27, Iss 5, p 151 (2022)
Utilizing viruses in the treatment of cancer, or oncolytic viral therapy (OVT), began in the 1950s with the idea that viruses could invade and destroy cancer cells. Barriers to this approach included a lack of specificity towards cancer cells and int
Externí odkaz:
https://doaj.org/article/01d916d5480a41fdab11f43351e0d8da
Autor:
Stijn Hentzen, Tomer Meirson, Kelly Koehn, Aaron M Goodman, Rajshekhar Chakraborty, Vinay Prasad, Douglas W. Sborov, Ghulam Rehman Mohyuddin
Publikováno v:
Blood. 140:7950-7951
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8bc753a62cdd3b1d46dce7a98b9f85f9
https://doi.org/10.1182/blood-2022-159807
https://doi.org/10.1182/blood-2022-159807
Understanding adult survivors of childhood cancers: An analysis of a survivorship transitions clinic
Publikováno v:
Journal of Clinical Oncology. 40:227-227
227 Background: As the prevalence of patients with cancer increases and improvements to treatment continue, the population of childhood cancer survivors (CCS) will see remarkable growth in coming years. Care for CCS requires collaboration between onc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aa987fa113edf16015d66b6c79399844
https://doi.org/10.1200/jco.2022.40.28_suppl.227
https://doi.org/10.1200/jco.2022.40.28_suppl.227
Autor:
Stijn Hentzen, Kathan Mehta, Raed Moh'd Taiseer Al-Rajabi, Anwaar Saeed, Joaquina Celebre Baranda, Stephen K. Williamson, Weijing Sun, Anup Kasi
Publikováno v:
Journal of Clinical Oncology. 40:504-504
504 Background: (177)Lu-Dotatate, a form of Peptide Receptor Radionuclide Therapy (PRRT), was approved by FDA for treatment of somatostatin-receptor-positive NETs in 2018. Clinical trials prior to the FDA approval of (177)Lu-Dotatate showed favorable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e561d0a0e93979de878e90f1c757fc21
https://doi.org/10.1200/jco.2022.40.4_suppl.504
https://doi.org/10.1200/jco.2022.40.4_suppl.504